| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Frailty consensus: a call to action.
|
J Am Med Dir Assoc
|
2013
|
6.54
|
|
2
|
Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging.
|
Circulation
|
2003
|
3.89
|
|
3
|
Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF).
|
Eur Heart J
|
2012
|
2.60
|
|
4
|
Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure.
|
J Am Coll Cardiol
|
2007
|
2.46
|
|
5
|
The relationship between cholesterol and survival in patients with chronic heart failure.
|
J Am Coll Cardiol
|
2003
|
2.12
|
|
6
|
Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial.
|
J Am Coll Cardiol
|
2012
|
2.11
|
|
7
|
Anemia and inflammation in COPD.
|
Chest
|
2005
|
1.83
|
|
8
|
Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.
|
Circ Heart Fail
|
2009
|
1.73
|
|
9
|
Anorexia in chronic obstructive pulmonary disease--association to cachexia and hormonal derangement.
|
Int J Cardiol
|
2006
|
1.58
|
|
10
|
Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity.
|
J Card Fail
|
2003
|
1.54
|
|
11
|
Nutritional recommendations for the management of sarcopenia.
|
J Am Med Dir Assoc
|
2010
|
1.51
|
|
12
|
Altered intestinal function in patients with chronic heart failure.
|
J Am Coll Cardiol
|
2007
|
1.48
|
|
13
|
The small intestine: a critical linkage in pathophysiology of cardiac cachexia.
|
Int J Cardiol
|
2010
|
1.46
|
|
14
|
PRESTO (a mammoth trial that could have been prevented), HPS and REMATCH.
|
Int J Cardiol
|
2002
|
1.38
|
|
15
|
The obesity paradox in chronic disease: facts and numbers.
|
J Cachexia Sarcopenia Muscle
|
2012
|
1.35
|
|
16
|
Body weight after stroke: lessons from the obesity paradox.
|
Stroke
|
2011
|
1.31
|
|
17
|
Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease.
|
J Cachexia Sarcopenia Muscle
|
2011
|
1.22
|
|
18
|
Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial.
|
Eur J Heart Fail
|
2011
|
1.20
|
|
19
|
Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
|
J Am Coll Cardiol
|
2007
|
1.18
|
|
20
|
Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure.
|
Cardiovasc Res
|
2006
|
1.17
|
|
21
|
IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia.
|
J Cachexia Sarcopenia Muscle
|
2011
|
1.12
|
|
22
|
Heat shock protein 70 in patients with chronic heart failure: relation to disease severity and survival.
|
Int J Cardiol
|
2004
|
1.11
|
|
23
|
Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF).
|
J Cachexia Sarcopenia Muscle
|
2010
|
1.10
|
|
24
|
The obesity paradox: weighing the benefit.
|
Eur Heart J
|
2009
|
1.10
|
|
25
|
Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure.
|
Int J Cardiol
|
2010
|
1.09
|
|
26
|
Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies.
|
J Cachexia Sarcopenia Muscle
|
2014
|
1.07
|
|
27
|
Ursodeoxycholic acid treatment in a rat model of cancer cachexia.
|
J Cachexia Sarcopenia Muscle
|
2011
|
1.06
|
|
28
|
Prevention of liver cancer cachexia-induced cardiac wasting and heart failure.
|
Eur Heart J
|
2013
|
1.06
|
|
29
|
How to determine a metabolically healthy body composition in cardiovascular disease.
|
J Am Coll Cardiol
|
2014
|
1.05
|
|
30
|
Muscle wasting in heart failure: An overview.
|
Int J Biochem Cell Biol
|
2013
|
1.04
|
|
31
|
Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure.
|
J Card Fail
|
2011
|
1.03
|
|
32
|
Novel treatment approaches to cachexia and sarcopenia: highlights from the 5th Cachexia Conference.
|
Expert Opin Investig Drugs
|
2010
|
1.02
|
|
33
|
Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure.
|
Eur J Heart Fail
|
2010
|
1.02
|
|
34
|
The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure.
|
Wien Klin Wochenschr
|
2009
|
1.02
|
|
35
|
Identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1.
|
PLoS One
|
2011
|
0.97
|
|
36
|
Effect of interleukin-10 on the production of tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with chronic heart failure.
|
Am J Cardiol
|
2002
|
0.97
|
|
37
|
Absolute and functional iron deficiency in professional athletes during training and recovery.
|
Int J Cardiol
|
2010
|
0.96
|
|
38
|
Stroke induced Sarcopenia: muscle wasting and disability after stroke.
|
Int J Cardiol
|
2013
|
0.95
|
|
39
|
Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders.
|
Heart Fail Clin
|
2009
|
0.92
|
|
40
|
Down-regulation of endothelial TLR4 signalling after apo A-I gene transfer contributes to improved survival in an experimental model of lipopolysaccharide-induced inflammation.
|
J Mol Med (Berl)
|
2010
|
0.92
|
|
41
|
Anaemia is an independent predictor of death in patients hospitalized for acute heart failure.
|
Clin Res Cardiol
|
2010
|
0.91
|
|
42
|
The relationship between tumor necrosis factor-α, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure.
|
Int J Cardiol
|
2009
|
0.91
|
|
43
|
Clinical characteristics and survival of patients with chronic heart failure and prolonged QRS duration.
|
Int J Cardiol
|
2002
|
0.91
|
|
44
|
Sarcopenia in stroke-facts and numbers on muscle loss accounting for disability after stroke.
|
J Cachexia Sarcopenia Muscle
|
2011
|
0.90
|
|
45
|
Prediction of mortality in chronic heart failure from peak oxygen consumption adjusted for either body weight or lean tissue.
|
J Card Fail
|
2004
|
0.90
|
|
46
|
Mechanism and novel therapeutic approaches to wasting in chronic disease.
|
Maturitas
|
2013
|
0.89
|
|
47
|
Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference.
|
J Cachexia Sarcopenia Muscle
|
2012
|
0.89
|
|
48
|
Overweight, obesity, and all-cause mortality.
|
JAMA
|
2013
|
0.89
|
|
49
|
Iron status and survival in diabetic patients with coronary artery disease.
|
Diabetes Care
|
2013
|
0.88
|
|
50
|
Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease.
|
Int J Cardiol
|
2012
|
0.88
|
|
51
|
The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats.
|
J Cachexia Sarcopenia Muscle
|
2013
|
0.87
|
|
52
|
TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy.
|
Int J Cardiol
|
2013
|
0.87
|
|
53
|
Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia.
|
Int J Cancer
|
2012
|
0.87
|
|
54
|
Inflammation in right ventricular dysfunction due to thromboembolic pulmonary hypertension.
|
Int J Cardiol
|
2009
|
0.86
|
|
55
|
Endothelial dysfunction of the peripheral vascular bed in the acute phase after ischemic stroke.
|
Cerebrovasc Dis
|
2011
|
0.86
|
|
56
|
Investigation of changes in body composition, metabolic profile and skeletal muscle functional capacity in ischemic stroke patients: the rationale and design of the Body Size in Stroke Study (BoSSS).
|
J Cachexia Sarcopenia Muscle
|
2013
|
0.86
|
|
57
|
Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia.
|
Int J Cardiol
|
2013
|
0.85
|
|
58
|
The relationship between age and production of tumour necrosis factor-alpha in healthy volunteers and patients with chronic heart failure.
|
Int J Cardiol
|
2003
|
0.85
|
|
59
|
Frailty and heart disease.
|
Int J Cardiol
|
2013
|
0.84
|
|
60
|
Uric acid as a prognostic marker in acute heart failure--new expectations from an old molecule.
|
Eur J Heart Fail
|
2007
|
0.84
|
|
61
|
Low-dose treatment with atorvastatin leads to anti-oxidative and anti-inflammatory effects in diabetes mellitus.
|
Eur J Pharmacol
|
2007
|
0.84
|
|
62
|
Whole blood endotoxin responsiveness in patients with chronic heart failure: the importance of serum lipoproteins.
|
Eur J Heart Fail
|
2005
|
0.84
|
|
63
|
Influence of diabetes mellitus and hyperglycemia on prognosis in patients > or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]).
|
Am J Cardiol
|
2010
|
0.83
|
|
64
|
Exercise capacity and body composition in living-donor renal transplant recipients over time.
|
Nephrol Dial Transplant
|
2009
|
0.83
|
|
65
|
The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy.
|
Int J Cardiol
|
2013
|
0.82
|
|
66
|
Nutrition in heart failure: an update.
|
Curr Opin Clin Nutr Metab Care
|
2009
|
0.82
|
|
67
|
The influence of recovery and training phases on body composition, peripheral vascular function and immune system of professional soccer players.
|
PLoS One
|
2009
|
0.81
|
|
68
|
Liver dysfunction and its nutritional implications in heart failure.
|
Nutrition
|
2012
|
0.81
|
|
69
|
Wasting of the left ventricle in patients with cardiac cachexia: a cardiovascular magnetic resonance study.
|
Int J Cardiol
|
2004
|
0.81
|
|
70
|
Resting energy expenditure and the effects of muscle wasting in patients with chronic heart failure: results from the Studies Investigating Comorbidities Aggravating Heart Failure (SICA-HF).
|
J Am Med Dir Assoc
|
2013
|
0.81
|
|
71
|
Insulin resistance in chronic heart failure.
|
J Am Coll Cardiol
|
2008
|
0.80
|
|
72
|
Effect of application route of the ghrelin analog BIM-28131 (RM-131) on body weight and body composition in a rat heart failure model.
|
Int J Cardiol
|
2013
|
0.80
|
|
73
|
Increased catabolic activity in adipose tissue of patients with chronic heart failure.
|
Eur J Heart Fail
|
2013
|
0.80
|
|
74
|
Cachexia in heart disease: highlights from the ESC 2010.
|
J Cachexia Sarcopenia Muscle
|
2011
|
0.80
|
|
75
|
Adiponectin resistance in heart failure and the emerging pattern of metabolic failure in chronic heart failure.
|
Circ Heart Fail
|
2010
|
0.79
|
|
76
|
Leukocyte redistribution: effects of beta blockers in patients with chronic heart failure.
|
PLoS One
|
2009
|
0.79
|
|
77
|
Hormonal consequences and prognosis of chronic heart failure.
|
Curr Opin Endocrinol Diabetes Obes
|
2011
|
0.79
|
|
78
|
Risk stratification in patients with chronic heart failure based on metabolic-immunological, functional and haemodynamic parameters.
|
Int J Cardiol
|
2010
|
0.79
|
|
79
|
Cardiac cachexia: hic et nunc: "hic et nunc" - here and now.
|
Int J Cardiol
|
2015
|
0.79
|
|
80
|
Cardiac cachexia is associated with right ventricular failure and liver dysfunction.
|
Int J Cardiol
|
2013
|
0.78
|
|
81
|
Differentiating between body fat and lean mass--how should we measure obesity?
|
Nat Clin Pract Endocrinol Metab
|
2008
|
0.78
|
|
82
|
The cardiac component of cardiac cachexia.
|
Am Heart J
|
2002
|
0.78
|
|
83
|
Intensified secondary prevention intending a reduction of recurrent events in TIA and minor stroke patients (INSPiRE-TMS): a protocol for a randomised controlled trial.
|
BMC Neurol
|
2013
|
0.78
|
|
84
|
Non-invasive assessment of cardiac hemodynamics in patients with advanced cancer and with chronic heart failure: a pilot feasibility study.
|
Arch Med Sci
|
2013
|
0.78
|
|
85
|
Furosemide induces mortality in a rat model of chronic heart failure.
|
Int J Cardiol
|
2011
|
0.78
|
|
86
|
Association of deranged adrenal steroid metabolism with anemia in chronic heart failure.
|
Am J Cardiol
|
2005
|
0.78
|
|
87
|
Obesity and the heart a weighty issue.
|
J Am Coll Cardiol
|
2006
|
0.77
|
|
88
|
Andropausal syndrome in men with systolic heart failure.
|
Pol Arch Med Wewn
|
2013
|
0.77
|
|
89
|
Usefulness of minimal modelling to assess impaired insulin sensitivity in patients with chronic heart failure.
|
Int J Cardiol
|
2009
|
0.77
|
|
90
|
Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia.
|
Int J Cardiol
|
2013
|
0.77
|
|
91
|
Abnormal serum calcium levels are associated with clinical response to maximization of heart failure therapy.
|
Pol Arch Med Wewn
|
2015
|
0.77
|
|
92
|
Diagnostic biomarkers in cardiovascular disease: the proteomics approach.
|
Eur Heart J
|
2012
|
0.76
|
|
93
|
Cellular endotoxin desensitization in patients with severe chronic heart failure.
|
Eur J Heart Fail
|
2005
|
0.76
|
|
94
|
Impact of Plasma Kynurenine Level on Functional Capacity and Outcome in Heart Failure - Results From Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF).
|
Circ J
|
2016
|
0.75
|
|
95
|
Uric acid in CHF: marker or player in a metabolic disease?
|
Int J Cardiol
|
2006
|
0.75
|
|
96
|
Metabolic disturbances in chronic heart failure: a case for the "macho" approach with testosterone?!
|
Eur J Heart Fail
|
2006
|
0.75
|
|
97
|
Value of serum pregnancy-associated plasma protein A for predicting cardiovascular events among patients presenting with cardiac chest pain.
|
CMAJ
|
2013
|
0.75
|
|
98
|
Anaemia predicts health related quality of life in heart failure patients.
|
Int J Cardiol
|
2012
|
0.75
|
|
99
|
Systolic heart failure.
|
N Engl J Med
|
2010
|
0.75
|
|
100
|
Questions in cardiac resynchronization therapy: metabolic implications.
|
J Am Coll Cardiol
|
2006
|
0.75
|
|
101
|
Survival and body fat in hemodialysis patients: true association or effects of concomitant therapy?
|
Am J Clin Nutr
|
2006
|
0.75
|
|
102
|
Revisiting the obesity paradox in heart failure: new insights?
|
Eur J Heart Fail
|
2011
|
0.75
|
|
103
|
Weight change with beta-blocker use: a side effect put into perspective.
|
Am J Med
|
2008
|
0.75
|
|
104
|
Mid-regional pro-atrial natriuretic peptide as a prognostic marker for all-cause mortality in patients with symptomatic coronary artery disease.
|
Clin Sci (Lond)
|
2012
|
0.75
|
|
105
|
Insulin sensitivity, but not hyperglycemia, may be superior as a prognostic marker and therapeutic target for diabetes in heart failure.
|
Am J Cardiol
|
2012
|
0.75
|
|
106
|
Heart failure therapy: testosterone replacement and its implications.
|
Eur Heart J
|
2005
|
0.75
|
|
107
|
Uric acid in chronic heart failure--current pathophysiological concepts.
|
Eur J Heart Fail
|
2008
|
0.75
|
|
108
|
Letter by Doehner et al regarding article, "Association between obesity and mortality after acute first-ever stroke: the obesity-stroke paradox".
|
Stroke
|
2011
|
0.75
|
|
109
|
Anabolic deficiencies in men with systolic heart failure: do co-morbidities and therapies really contribute significantly?
|
Aging Male
|
2013
|
0.75
|
|
110
|
Assessment of serum cotinine in patients with chronic heart failure: self-reported versus objective smoking behaviour.
|
Clin Res Cardiol
|
2012
|
0.75
|
|
111
|
Meeting highlights from the 2013 European Society of Cardiology Heart Failure Association Winter Meeting on Translational Heart Failure Research.
|
Eur J Heart Fail
|
2013
|
0.75
|
|
112
|
Overview of emerging pharmacotherapy in chronic heart failure.
|
Expert Opin Pharmacother
|
2009
|
0.75
|
|
113
|
Sinus rhythm versus atrial fibrillation in elderly patients with chronic heart failure--insight from the Cardiac Insufficiency Bisoprolol Study in Elderly.
|
Int J Cardiol
|
2012
|
0.75
|
|
114
|
[Diagnostic and treatment principles of iron deficiency anaemia].
|
MMW Fortschr Med
|
2015
|
0.75
|
|
115
|
Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and heart failure.
|
J Hypertens
|
2016
|
0.75
|